







































































































cemia of malignancy ; HMM）と，癌の広範な骨転移や浸
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Hypercalcemia in patients with end-stage cancer
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１）Division of Palliative Care,２）Division of General Medicine, Kondo-Naika Hospital, Tokushima, Japan
SUMMARY
Hypercalcemia develops in patients with advanced cancer and severely deteriorates their
quality of life. This study aimed to evaluate the influence of hypercalcemia on the clinical course
of patients with end-stage cancer. This retrospective study included data on２５３patients who had
cancer and died in the palliative care unit at Kondo-Naika Hospital in２００８and２００９. Of these pa-
tients, １６（６．３％）developed hypercalcemia during hospitalization before death. These１６ pa-
tients included５patients with lung cancer ;４with esophageal cancer ;２with pancreatic cancer ;
and１patient each with liver cancer, breast cancer, gall bladder cancer, renal cancer, or gastric can-
cer. The incidence of esophageal cancer in the patients with hypercalcemia was significantly
higher than that in the patients who did not have hypercalcemia（p＜０．０１）. Of the１６patients
with hypercalcemia,１０had bone metastasis, whereas the other６patients had hypercalcemia even
without bone metastasis. The main symptom of hypercalcemia was drowsiness in７patients, de-
lirium in６patients, and general fatigue in３patients. Fifteen patients were treated using bisphos-
phonates. After the hypercalcemia was detected, the１６patients survived for only a short time,
with a mean survival time of１６．９days. In particular, the mean survival time of ７ patients who
did not respond to treatment for hypercalcemia was only６．０days, and１patient with a calcium
level of１９．１mg／dl died the day after zoledronic acid hydrate therapy was initiated. Thus,
hypercalcemia in patients with end-stage cancer seems to indicate extremely critical conditions
with the worst prognosis.
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